Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3-Pillars combination treatment for early hormone receptor-positive HER2-positive breast cancer
ISRCTN37422164Phase 2Completed
- Sponsor
- University of Liverpool
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of tucatinib, palbociclib, letrozole and trastuzumab in breast cancer, sponsored by University of Liverpool. Primary endpoint: Pathological complete response rate. Started Aug 2024; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN37422164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN37422164.